Global law firm Baker McKenzie advised Bristol Myers Squibb (BMS) in a strategic collaboration and license agreement with Amphista. This collaboration will leverage Amphista's proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics. Amphista will receive a USD 30 million upfront payment, the potential for up to USD 1.25 billion in performance-based milestone payments and payment for a limited expansion of the collaboration, as well as royalties on global net sales of products. The closing of the transaction is subject to the parties obtaining regulatory clearances or approvals.
The Baker McKenzie team that advised BMS was led by Oren Livne (New York/Princeton) with assistance from Robby Turner (Dallas). The team included Creighton Macy (Washington, DC), Paul Johnson (Brussels), Daniel Graulich (Washington DC), Anthony Gamble (London), Zeyang Gao (London), Priyanka Usmani (London) and Matthieu Hucker (London).
Baker McKenzie is a transactional powerhouse, with more than 2,500 deal lawyers in over 46 countries offering leading expertise in the areas most critical for our clients. We excel in complex transactions and cross-border deals – over 60% of our deals are multi-jurisdictional. We are global and local, combining money-market sophistication with local excellence. In 2021 alone, the US Transactions Team handled 15 multi-billion dollar mergers and acquisitions. The Firm's Life Sciences team includes 800 dedicated Healthcare & Life Sciences lawyers worldwide, bringing our vast industry transactional experience to work for our clients, in addition to collaborating with our IP and regulatory colleagues around the world.